SEC Form 4 · accession 0001193125-26-335820
Septerna, Inc. · SEPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel D. Long
Officer — SVP, Drug Discovery
Period of report
Aug 3, 2026
Accepted (ET)
Aug 5, 2026 · 7:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001984086
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 3, 2026 | M | 1,816 | $2.76 | A | 98,228 | D | |
| Common Stock | Aug 3, 2026 | M | 1,518 | $2.76 | A | 99,746 | D | |
| Common StockF2 | Aug 3, 2026 | S | 1,000 | $33.9756 | D | 98,746 | D | |
| Common StockF3 | Aug 3, 2026 | S | 2,334 | $34.6805 | D | 96,412 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $2.76 | Aug 3, 2026 | M | 1,816 | D | — | Nov 11, 2033 | Common Stock | 1,816 | 5,227 | D |
| Stock Option (Right to Buy)F5 | $2.76 | Aug 3, 2026 | M | 1,518 | D | — | Mar 19, 2034 | Common Stock | 1,518 | 12,418 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.39 to $34.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.43 to $35.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F41/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F51/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.